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TO THE EDITOR:
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We read with interest the recent article by Zamora et al describing that letermovir prophylaxis following allo-
geneic hematopoietic stem cell transplantation (allo-HSCT) may be associated with delayed reconstitution
of cytomegalovirus (CMV)-specific T-cell immunity.1 They hypothesize that this may be due to decreased
exposure to CMV antigen. CMV infection is a cause of significant morbidity and mortality following allo-
HSCT where an absolute and functional deficiency of CMV-reactive T lymphocytes can lead to the develop-
ment of CMV disease.2 In the pivotal phase 3 randomized clinical trial by Marty et al,3 letermovir prophylaxis
given for 14 weeks following transplantation was shown to reduce the risk of clinically significant CMV infec-
tion (as defined as CMV disease or CMV viremia leading to preemptive therapy) by week 24 when com-
pared with placebo. This led to UK National Health Service approval of the use of letermovir therapy in July
2019 as prophylaxis against CMV for the first 100 days posttransplant in CMV-seropositive allo-HSCT
recipients. Although many patients in the United Kingdom receive alemtuzumab as graft-versus-host disease
(GVHD) prophylaxis, only 12 patients (3.2%) in the letermovir group and 11 patients (5.7%) in the placebo
group received alemtuzumab in the phase 3 clinical trial.3 In view of these small numbers, it remains unclear
whether letermovir prophylaxis is effective at reducing the risk of clinically significant CMV infection in this
group and whether that benefit remains once the letermovir therapy is ceased. Alemtuzumab-containing reg-
imens are associated with both delayed CMV-specific immune reconstitution and relatively high CMV reacti-
vation rates.4,5 It is therefore possible that these patients would be at particularly high risk of CMV infection
following cessation of letermovir at day 100, particularly if decreased CMV antigen exposure results in fur-
ther delayed CMV-specific immune reconstitution as hypothesized by Zamora et al.
In an attempt to address these issues, we performed a United Kingdom–based multicenter retrospective
study of allogeneic HSCT recipients who received alemtuzumab as GVHD prophylaxis and letermovir for
the first 100 days posttransplant. Twelve transplant centers contributed data on patients transplanted
between July 2019 and August 2020. All transplant recipients were CMV seropositive with a require-
ment for at least 50 days of follow-up or until death if this was earlier. We used a historical comparator
cohort of 234 consecutive CMV-seropositive recipients who received alemtuzumab-based
T-cell–depleted allo-HSCT at our institution between the dates of January 2006 and February 2017 and
did not receive letermovir prophylaxis. All patients had consented to collection of baseline data regarding
the collected parameters for registry reporting. Statistical analyses were performed using NCSS 2020,
and a P value ,.05 was considered statistically significant. Cumulative incidences were calculated for
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CMV detection and clinically significant CMV infection rates, with
death without infection or clinically significant CMV infection,
respectively, being the competing risks.
Patient characteristics are shown in Table 1. The majority (102/
110, 92.7%) received letermovir at a dose of 240 mg once daily
because of concomitant ciclosporin therapy. Compared with the
comparator group, there was a significant decrease in the
cumulative incidence of detection of a quantifiable CMV viral
load by week 40 (51.5% [39.8% to 66.6%] vs 90.3% [86.6%
to 94.2%]; P value ,.0001; Figure 1A). The temporal kinetic of
detection in the letermovir group mirrored that in the registration
study, with a cumulative incidence of 13.2% (8.1% to 21.6%) at
week 14 and 44.7% (34.3% to 58.3%) at week 24. The cumu-
lative incidence of clinically significant CMV infection was 6.8%
(3.3% to 14.0%) at week 14 and 33.0% (23.3% to 46.7%) at
week 24 (Figure 1B) compared with 81.6% (76.8% to 86.7%)
and 83.8% (79.2% to 88.6%), respectively, in the comparator
cohort (P value ,.0001), with no statistically significant differ-
ence according to donor type (Figure 1C). By comparison, the
incidence proportion was 7.7% at week 14 and 17.5% at week
24 in the registration study (with a Kaplan-Meier event rate of
18.9% [14.4% to 23.5%] at week 24). It is notable that
although patients receiving alemtuzumab were considered “low
risk” in the registration study, their outcomes more closely
approximated those of the predefined “high-risk” cohort in terms
of the increased incidence between week 14 and week 24,
which was noted to relate closely to GVHD and glucocorticoid
use in that cohort. Relatively few patients receiving alemtuzumab
develop higher grades of GVHD. An exploratory analysis of
development of clinically significant CMV infection after week
14 according to GVHD status (Figure 1D) illustrates that the
main driver of the late increase is within the larger cohort with
grade 0 to 1 GVHD and more likely associated with delayed
immune reconstitution rather than enhanced immune suppres-
sion. Numbers in the grade 2 to 4 GVHD group limit definitive
interpretation with no statistically significant difference between
the curves, although it remains probable that this group does
particularly poorly because of the combination of both delayed
immune reconstitution and enhanced immune suppression.
Despite the relatively high incidence of late CMV events in the
alemtuzumab cohort, the high levels of viremia and need for pre-
emptive therapy without letermovir prophylaxis means that the
potential therapeutic benefit and cost-effectiveness of letermovir
is, however, perhaps even greater in the setting of transplants
incorporating alemtuzumab. The treatment difference (letermo-
vir-placebo) in terms of clinically significant CMV infection
through week 24 was estimated at 223.5% in the registration
study, but likely approaches double that in the setting of
alemtuzumab-based transplants (250.8% in our analysis). Even
considering that clinically significant CMV events continued to
occur after week 24 in our study, reaching a level of 39.9% by
week 32, the treatment difference likely exceeds 40%. Thus,
despite any additional impact letermovir may have to that of
alemtuzumab-mediated T-cell depletion on slowing immune
reconstitution, overall clinical benefit appears to be maintained
in this group. Our data raise the question of how much addi-
tional benefit would be gained by prolonging letermovir prophy-
laxis in these patients. The current extension study (MK-8228-
040, #NCT03930615) evaluating prolongation of prophylaxis to
day 200 following allo-HSCT includes patients receiving alemtu-
zumab and will help to address this issue. Whether letermovir
significantly delays immune reconstitution still further as indi-
cated by the observation of Zamora et al, resulting in temporal
displacement of a significant ongoing risk to later time points
when patient follow-up is generally less frequent, will be an
important factor in determining its optimal deployment. The eval-
uation of T-cell reconstitution and CMV-specific immunity
parameters should be incorporated into future prospective stud-
ies as they will be critical for a deeper understanding of the
issues raised and potential refinement of therapeutic strategies.
We await the results of prospective clinical trials investigating
this issue with interest.





No. of patients 110 234
Median follow-up (d) 131 (3-311) 688 (21-4158)












Aplastic anemia 8 0
MPD/myelofibrosis 0 3
CML/CMML 8 1







Reduced intensity 100 192
Maximum GVHD grade
0 to 1 79 170
2 20 44
3 to 4 7 19
Unknown 4 1
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic
lymphocytic leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic
leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; MMUD,
mismatched unrelated donor; MUD, matched unrelated donor; Neg, Negative; PLL,
prolymphocytic leukemia; Pos, positive.






































































































Acknowledgment: The authors thank Shu Wong for her contribu-
tion to the data collection.
Contribution: M.A.V.M. and K.S.P. designed and performed the
research, analyzed the data, and wrote the paper; V.M., K.J.T., E.T.,
A.J.C.B., A.P., R.L., K.O., A.P., E.N., J.A.S., J.B., A.K., M.H.G., G.E.,
S.L., E.H., N.D., J.P., P.C., B.C., and A.P. performed the research,
supplied the data, and reviewed the paper.
Conflict-of-interest disclosure: V.M. received research grants
from MSD/Gilead and speakership from MSD, Gilead, Pfizer, Novar-
tis, Jazz, Incyte. E.T. declares advisory boards for Celgene, Gilead/
Kite, Jazz, Novartis, Pfizer and MSD, speaker fees for Gilead/Kite,
Janssen, Jazz, Novartis, and Pfizer and consultancy for educational
materials for Gilead/Kite. A.P. declares advisory board for MSD. R.L.
received educational grants and speaker fees for MSD, Chugai
Pharma, Astellas, Gilead, and Sanofi. E.N. declares advisory boards
for Kite/Gilead, Novartis, BMS/Celgene, and Pfizer and conference
support for Kite/Gilead, Novartis, and speaker fees for Kite/Gilead.
J.A.S. declares honoraria for educational events supported by Jazz,
Mallinckrodt, Gilead, Janssen, and Actelion, advisory board participa-
tion for Medac, and IDMC membership for a Kiadis Pharma sup-
ported clinical trial, none of which are directly related to this study.
E.H. received honoraria from MSD. K.S.P. received speaker fees
from Merck. The remaining authors declare no competing financial
interests.
ORCID profiles: M.A.V.M., 0000-0002-8928-9386; V.M.,
0000-0001-6572-0971; A.J.C.B., 0000-0003-4550-220X; A.P.,
0000-0002-4905-6860; K.O., 0000-0003-2276-3925; E.N.,
0000-0002-6439-0795; J.A.S., 0000-0001-6819-3476; A.K.,
0000-0001-6432-6999; N.D., 0000-0002-1191-8170; B.C.,
0000-0002-7914-0799.
Correspondence: Maria A. V. Marzolini, Department of Haema-
tology, UCL Cancer Institute, University College London, Lon-
don. United Kingdom e-mail: m.marzolini@ucl.ac.uk.
References
1. Zamora D, Duke ER, Xie H, et al. Cytomegalovirus-specific T-cell
reconstitution following letermovir prophylaxis after hematopoietic
cell transplantation. Blood. 2021;138(1):34-43.
2. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic
T-lymphocyte response to cytomegalovirus after human allogeneic

































































































Figure 1. (A) Cumulative incidence of detection of quantifiable CMV according to use of letermovir as prophylaxis. (B) Cumulative incidence of clinically significant CMV
infection. (C) Cumulative incidence of preemptive CMV therapy in patients who received letermovir by donor type. (D) Cumulative incidence of clinically significant CMV
infection in patients receiving letermovir with at least 14 weeks follow-up according to GVHD severity. UD, unrelated donor.
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